Effect and risk factor of adverse drug events in using dapaglilfozin with type 2 diabetes mellitus patients.

  • At: 2017 FIP Congress in Seoul (South Korea)
  • Type: Poster
  • By: KIM, Kwi (Seoul National University Hospital, Pharmacy, Seoul, Korea, Republic Of)
  • Co-author(s): Kwi Suk Kim: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Hyung Woo Lee: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Sun Joon Moon: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
    Hee Sim Han: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Eun Jeong Shin: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Jin Hee Baek: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Yoon Sook Cho: Pharmacy, Seoul National University Hospital, Seoul, Korea, Republic Of
    Young Min Cho: Division of Endocrinology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea, Republic Of
  • Abstract:

    Methods

    US">As an institutional pharmacovigilance review activity, we reviewed data from medical records of 455 patients with type 2 diabetes who received dapagliflozin therapy from July 2014 to August 2015 in Seoul National University Hospital. We analyzed the change of laboratory data and examined the characteristics of dapagliflozin users who..

  • The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress. Please login